Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BRAF inhibitor activity in V600R metastatic melanoma--response.

Literature DB >> 23490649

BRAF inhibitor activity in V600R metastatic melanoma--response.

Oliver Klein, Arthur Clements, Alexander M Menzies, Sandra O'Toole, Richard F Kefford, Georgina V Long.

Abstract

Entities: Disease Gene Mutation

Mesh：

Substances：

Year: 2013 PMID： 23490649 DOI： 10.1016/j.ejca.2013.02.010

Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

Review 1. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.

Authors: Eva Muñoz-Couselo; Jesús Soberino García; José Manuel Pérez-García; Vanesa Ortega Cebrián; Javier Cortés Castán
Journal: Ann Transl Med Date: 2015-09

2. Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.

Authors: Charlotte R Pfeifer; Cory M Alvey; Jerome Irianto; Dennis E Discher
Journal: Curr Opin Syst Biol Date: 2017-04-27

Review 3. Molecular pathology of cutaneous melanoma.

Authors: Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal: Melanoma Manag Date: 2014-12-04

Review 4. Melanoma: What do all the mutations mean?

Authors: Elizabeth J Davis; Douglas B Johnson; Jeffrey A Sosman; Sunandana Chandra
Journal: Cancer Date: 2018-04-17 Impact factor: 6.860

5. Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.

Authors: Masaru Ide; Shinichi Koba; Naoko Sueoka-Aragane; Akemi Sato; Yuri Nagano; Takuya Inoue; Noriyuki Misago; Yutaka Narisawa; Shinya Kimura; Eisaburo Sueoka
Journal: Pathol Oncol Res Date: 2016-10-21 Impact factor: 3.201

BRAF inhibitor activity in V600R metastatic melanoma--response.

Review 1. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.

2. Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.

Review 3. Molecular pathology of cutaneous melanoma.

Review 4. Melanoma: What do all the mutations mean?

5. Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.

Review 6. The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Review 7. Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.

8. Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?